At the news
? NEUTRALIMPACT 2/10 8-K filed Aug 10, 2026 at 08:43 ET
Fulcrum Therapeutics VP of Finance and principal accounting officer Greg Tourangeau mutually agreed to depart, effective August 7, 2026. CFO Alan Musso has been appointed as the new principal accounting officer, effective the same date, receiving no additional compensation. This is a routine internal realignment of accounting officer duties with no financial impact.
- Greg Tourangeau departed as VP of Finance and principal accounting officer on August 7, 2026, per a mutual agreement first disclosed on June 11, 2026.
- Alan Musso, the company's CFO and principal financial officer, was appointed principal accounting officer effective August 7, 2026.
- Musso will receive no additional compensation for the additional role.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access